All In Biotech

Drug Trial Radar · NCT07872306

A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Period to Evaluate the Safety, Tolerability, and Efficacy of SAT-3247 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Dec 15, 2026

Primary completion

Dec 30, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Satellos Bioscience, Inc.Industry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD

Conditions

  • Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions

  • forazapadinDrug

    Forazapadin (SAT 3247) is a potent, orally available, muscle penetrant, small molecule inhibitor of AAK1

  • Placebo ComparatorDrug

    Matching placebo oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation of forazapadin in FSHDTime frame: 48 weeks
  2. Efficacy of forazapadin as treatment in FSDHTime frame: 24 and 48 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.